Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection.

  2015cited by this paper
• AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges

  2015cited by this paper
• Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection

  2015cited by this paper
• Antibodies VRC01 and 10E8 Neutralize HIV-1 with High Breadth and Potency Even with Ig-Framework Regions Substantially Reverted to Germline

  2014cited by this paper
• Enhanced neonatal Fc receptor function improves protection against primate SHIV infection

  2014cited by this paper
• Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo

  2014cited by this paper
• Antibody-based Protection Against HIV Infection

  2014cited by this paper
• Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques

  2014cited by this paper
• Vectored Immunoprophylaxis Protects Humanized Mice From Mucosal HIV Transmission

  2014cited by this paper
• Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection

  2014cited by this paper
• Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor

  2014cited by this paper
• Broad protection against influenza infection by vectored immunoprophylaxis in mice

  2013cited by this paper
• Immunogenicity of mAbs in non-human primates during nonclinical safety assessment

  2013cited by this paper
• Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning

  2013cited by this paper
• Nonhuman primate models in AIDS research

  2013cited by this paper
• Two Distinct Broadly Neutralizing Antibody Specificities of Different Clonal Lineages in a Single HIV-1-Infected Donor: Implications for Vaccine Design

  2012cited by this paper
• High-Resolution Definition of Vaccine-Elicited B Cell Responses Against the HIV Primary Receptor Binding Site

  2012cited by this paper
• Broad and potent neutralization of HIV-1 by a gp41-specific human antibody

  2012cited by this paper
• Pharmacological Modulation of Humoral Immunity in a Nonhuman Primate Model of AAV Gene Transfer for Hemophilia B

  2012cited by this paper
• Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo

  2012cited by this paper
• Optimization and qualification of an 8-color intracellular cytokine staining assay for quantifying T cell responses in rhesus macaques for pre-clinical vaccine studies.

  2012cited by this paper
• Host cell species-specific effect of cyclosporine A on simian immunodeficiency virus replication

  2012cited by this paper
• Antibody gene transfer for HIV immunoprophylaxis

  2012cited by this paper
• Single-Chain Fv-Based Anti-HIV Proteins: Potential and Limitations

  2011cited by this paper
• Broad neutralization coverage of HIV by multiple highly potent antibodies

  2011cited by this paper
• A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield

  2011cited by this paper
• Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

  2011cited by this paper
• The role of antibodies in HIV vaccines.

  2010cited by this paper
• Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1

  2010cited by this paper
• Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques

  2009cited by this paper
• Passive immunization with human neutralizing monoclonal antibodies against HIV-1 in macaque models: experimental approaches.

  2009cited by this paper
• Broadly Neutralizing Monoclonal Antibodies 2F5 and 4E10 Directed against the Human Immunodeficiency Virus Type 1 gp41 Membrane-Proximal External Region Protect against Mucosal Challenge by Simian-Human Immunodeficiency Virus SHIVBa-L

  2009cited by this paper
• Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys

  2009cited by this paper
• Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target

  2009cited by this paper
• P09-05. Mechanism of HIV-1 resistance to a monoclonal antibody that effectively targets the site of CD4 attachment

  2009cited by this paper
• Frequency and Phenotype of Human Immunodeficiency Virus Envelope-Specific B Cells from Patients with Broadly Cross-Neutralizing Antibodies

  2008cited by this paper
• An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo.

  2007cited by this paper
• Passive immunization as tool to identify protective HIV-1 Env epitopes.

  2007cited by this paper
• Broad HIV-1 neutralization mediated by CD4-binding site antibodies

  2007cited by this paper
• Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid

  2006cited by this paper
• Immunogenicity of engineered antibodies.

  2005cited by this paper
• Stable antibody expression at therapeutic levels using the 2A peptide

  2005cited by this paper
• Antibody humanization by CDR grafting.

  2004cited by this paper
• Defining the protective antibody response for HIV-1.

  2003cited by this paper
• AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.

  2003cited by this paper
• Generation of Neutralizing Activity against Human Immunodeficiency Virus Type 1 in Serum by Antibody Gene Transfer

  2002cited by this paper
• ALVAC-SIV-gag-pol-env-Based Vaccination and Macaque Major Histocompatibility Complex Class I (A*01) Delay Simian Immunodeficiency Virus SIVmac-Induced Immunodeficiency

  2002cited by this paper
• Influence of Vector Dose on Factor IX-Specific T and B Cell Responses in Muscle-Directed Gene Therapy

  2002cited by this paper
• Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis

  2001cited by this paper
• Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro

  2001cited by this paper
• Localization dose and time of antigens determine immune reactivity.

  2000cited by this paper
• Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

  2000cited by this paper
• Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector

  1999cited by this paper
• Cyclophilin A is required for the replication of group M human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus SIV(CPZ)GAB but not group O HIV-1 or other primate immunodeficiency viruses

  1996cited by this paper
• Functional association of cyclophilin A with HIV-1 virions

  1994cited by this paper
• Rhesus Monkey Responses to Multiple Injections of Human Monoclonal Antibodies

  1987cited by this paper
• A Theory of Self-Nonself Discrimination

  1970cited by this paper

• No citing papers are available for this paper.